Relationship Between Raltegravir Trough Plasma Concentration and Virologic Response and the Impact of Therapeutic Drug Monitoring During Pregnancy

Overview

Journal Int J STD AIDS

Specialty Infectious Diseases

Date 2022 Dec 18

PMID 36529684

Authors

Sabrina Carvalho

Nancy L Sheehan

Silvie Valois

Fatima Kakkar

Marc Boucher

Ema Ferreira

Isabelle Boucoiran

Affiliations

Soon will be listed here.

Abstract

Background: Limited data is available on raltegravir (RAL) pharmacokinetics during pregnancy and the value of therapeutic drug monitoring (TDM) in pregnancy is unknown. This study aims to describe RAL trough plasma concentrations (C) during pregnancy and review the impact of RAL TDM on outcomes.

Methods: Women from the prospective mother-infant HIV cohort of Mother and Children's Infectious Diseases Center who received RAL during their pregnancy between 2011-2020 were included. TDM reports were reviewed and C values estimated when possible, using historical RAL half-lives.

Results: We included 76 pregnant women of which 47 underwent TDM. We observed a significant association between virological response and C (-value .034) with an increase of 0.1 mg/L corresponding to a 2.96 reduction in the risk of having a detectable viral load. The results indicated that in pregnant women a RAL C threshold of 0.04 mg/L has a higher specificity (75%) as compared to our current C target value of 0.02 mg/L (25%) and an acceptable sensitivity (77%). No significant differences were observed between C at each trimester. When comparing pregnancies with and without TDM, no statistically significant differences were observed in the virologic response during pregnancy and at delivery, or with the need for triple antiretroviral prophylaxis in newborns.

Conclusions: An association between RAL C and viral load was observed and achieving a RAL C of 0.04 mg/L or greater is a predictor of virologic response in pregnant women. The impact of TDM in pregnancy, however, could not be demonstrated.

References

Buckoreelall K, Cressey T, King J . Pharmacokinetic optimization of antiretroviral therapy in pregnancy. Clin Pharmacokinet. 2012; 51(10):639-59. DOI: 10.1007/s40262-012-0002-0. View

Markowitz M, Morales-Ramirez J, Nguyen B, Kovacs C, Steigbigel R, Cooper D . Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr. 2006; 43(5):509-15. DOI: 10.1097/QAI.0b013e31802b4956. View

OKelly B, Murtagh R, Lambert J . Therapeutic Drug Monitoring of HIV Antiretroviral Drugs in Pregnancy: A Narrative Review. Ther Drug Monit. 2020; 42(2):229-244. DOI: 10.1097/FTD.0000000000000735. View

Momper J, Best B, Wang J, Capparelli E, Stek A, Barr E . Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV. AIDS. 2018; 32(17):2507-2516. PMC: 6209536. DOI: 10.1097/QAD.0000000000001992. View

Mor G, Cardenas I . The immune system in pregnancy: a unique complexity. Am J Reprod Immunol. 2010; 63(6):425-33. PMC: 3025805. DOI: 10.1111/j.1600-0897.2010.00836.x. View

Gilleece D, Tariq D, Bamford D, Bhagani D, Byrne D, Clarke D . British HIV Association guidelines for the management of HIV in pregnancy and postpartum 2018. HIV Med. 2019; 20 Suppl 3:s2-s85. DOI: 10.1111/hiv.12720. View

Garrido C, de Mendoza C, Alvarez E, Garcia F, Morello J, Garcia S . Plasma raltegravir exposure influences the antiviral activity and selection of resistance mutations. AIDS Res Hum Retroviruses. 2011; 28(2):156-64. DOI: 10.1089/AID.2010.0370. View

Peters H, Francis K, Sconza R, Horn A, Peckham C, Tookey P . UK Mother-to-Child HIV Transmission Rates Continue to Decline: 2012-2014. Clin Infect Dis. 2017; 64(4):527-528. DOI: 10.1093/cid/ciw791. View

Watts D, Stek A, Best B, Wang J, Capparelli E, Cressey T . Raltegravir pharmacokinetics during pregnancy. J Acquir Immune Defic Syndr. 2014; 67(4):375-81. PMC: 4213295. DOI: 10.1097/QAI.0000000000000318. View

10.

Bukkems V, Post T, Colbers A, Burger D, Svensson E . A population pharmacokinetics analysis assessing the exposure of raltegravir once-daily 1200 mg in pregnant women living with HIV. CPT Pharmacometrics Syst Pharmacol. 2020; 10(2):161-172. PMC: 7894397. DOI: 10.1002/psp4.12586. View

11.

Renet S, Closon A, Brochet M, Bussieres J, Boucher M . Increase in transaminase levels following the use of raltegravir in a woman with a high HIV viral load at 35 weeks of pregnancy. J Obstet Gynaecol Can. 2013; 35(1):68-72. DOI: 10.1016/s1701-2163(15)31051-3. View

12.

Clavel C, Peytavin G, Tubiana R, Soulie C, Crenn-Hebert C, Heard I . Raltegravir concentrations in the genital tract of HIV-1-infected women treated with a raltegravir-containing regimen (DIVA 01 study). Antimicrob Agents Chemother. 2011; 55(6):3018-21. PMC: 3101453. DOI: 10.1128/AAC.01460-10. View

13.

Genders T, Spronk S, Stijnen T, Steyerberg E, Lesaffre E, Hunink M . Methods for calculating sensitivity and specificity of clustered data: a tutorial. Radiology. 2012; 265(3):910-6. DOI: 10.1148/radiol.12120509. View

14.

Zheng Y, Hirt D, Delmas S, Lui G, Benaboud S, Lechedanec J . Effect of Pregnancy on Unbound Raltegravir Concentrations in the ANRS 160 RalFe Trial. Antimicrob Agents Chemother. 2020; 64(10). PMC: 7508578. DOI: 10.1128/AAC.00759-20. View

15.

Eron Jr J, Rockstroh J, Reynes J, Andrade-Villanueva J, Ramalho-Madruga J, Bekker L . Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis. 2011; 11(12):907-15. DOI: 10.1016/S1473-3099(11)70196-7. View

16.

Rizk M, Hang Y, Luo W, Su J, Zhao J, Campbell H . Pharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatment-naive HIV-infected patients. Antimicrob Agents Chemother. 2012; 56(6):3101-6. PMC: 3370742. DOI: 10.1128/AAC.06417-11. View

17.

Blonk M, Colbers A, Hidalgo-Tenorio C, Kabeya K, Weizsacker K, Haberl A . Raltegravir in HIV-1-Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy. Clin Infect Dis. 2015; 61(5):809-16. DOI: 10.1093/cid/civ366. View

18.

Kakkar F, Boucoiran I . The Women and Children's Infectious Diseases Center: An integrated approach to congenital infectious diseases. Clin Invest Med. 2019; 41(4):E211-E212. DOI: 10.25011/cim.v41i4.32223. View

19.

Krishna R, East L, Larson P, Valiathan C, Butterfield K, Teng Y . Effect of metal-cation antacids on the pharmacokinetics of 1200 mg raltegravir. J Pharm Pharmacol. 2016; 68(11):1359-1365. DOI: 10.1111/jphp.12632. View

20.

Winston A, Bloch M, Carr A, Amin J, Mallon P, Ray J . Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy. J Antimicrob Chemother. 2005; 56(2):380-7. DOI: 10.1093/jac/dki235. View